Abstract
Addressing COVID-19 Barriers to Clinical Trial Enrollment and Implementation in the PHARM-DC Study
Innovation in aging, Vol.5(Suppl. 1), p.103
01/01/2021
DOI: 10.1093/geroni/igab046.393
PMCID: PMC8680858
Abstract
Abstract Recent hospitalization puts older adults at higher risk of experiencing adverse drug events (ADEs) that are a common cause of hospital readmission. Yet, most ADEs are preventable. The PHARMacist Discharge Care (PHARM-DC) study is a multi-site randomized controlled trial that seeks to evaluate the effect of pharmacist-led peri- and post-discharge interventions on 30-day hospital readmissions among older adults taking ≥10 medications or ≥3 high-risk medications. The PHARM-DC intervention includes pharmacist-led patient counseling, medication reconciliation at discharge, and a follow-up phone call post-discharge. We will highlight study protocol adaptations undertaken during the COVID-19 pandemic to address challenges to enrollment and to minimize risk of COVID-19 exposure for study participants and research personnel. Additionally, we will share insights from focus groups and semi-structured interviews with pharmacist interventionists and pharmacy leaders on barriers and facilitators to implementation due to the pandemic and strategies for future clinical trials to overcome barriers.
Details
- Title: Subtitle
- Addressing COVID-19 Barriers to Clinical Trial Enrollment and Implementation in the PHARM-DC Study
- Creators
- Joshua PevnickMichelle KellerKorey KenneltyMichelle KoLogan MurryAn NguyenAndrew HenreidJeffrey Schnipper
- Resource Type
- Abstract
- Publication Details
- Innovation in aging, Vol.5(Suppl. 1), p.103
- DOI
- 10.1093/geroni/igab046.393
- PMCID
- PMC8680858
- ISSN
- 2399-5300
- Publisher
- Oxford
- Language
- English
- Date published
- 01/01/2021
- Academic Unit
- Family and Community Medicine; Pharmacy Practice and Science; Injury Prevention Research Center
- Record Identifier
- 9984521373602771
Metrics
16 Record Views